Sign in to view content

Efficacy, Durability, and Safety of Faricimab in DME: 2-Year Results From the Phase 3 YOSEMITE and RHINE Trials

Jennifer I. Lim, MD, FARVO, FASRS

Video
Published 2022

Related

Phase 3 Randomized, Double-Masked Studies of Brolucizumab Versus Aflibercept in nAMD: Expanded Primary and Secondary Outcomes From HAWK/HARRIER
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2018
Characteristics and the Need for Supplementation Following 0.19mg Fluocinolone Acetonide (FAc) in Diabetic Macular Edema (DME) Patients
Victor Hugo Gonzalez, MD
Annual Meeting Talks
2021
Diabetic Retinopathy 2 Symposium
Annual Meeting Talks
2020

Category: Diabetic Retinopathy

See more